Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0170805
Title: GAD1 gene expression in blood of patients with first-episode psychosis
Authors: Yee J.Y.
Nurjono M. 
Teo S.R. 
Lee T.-S. 
Lee J. 
Keywords: 4 aminobutyric acid
chlorpromazine
glutamate decarboxylase
glutamate decarboxylase 1
glutamate decarboxylase 65
glutamate decarboxylase 67
messenger RNA
unclassified drug
glutamate decarboxylase
glutamate decarboxylase 1
adult
Article
blood sampling
cerebrospinal fluid analysis
controlled study
disease duration
dopaminergic transmission
female
GABAergic system
gene expression
human
lifespan
major clinical study
male
neurotransmission
polymerase chain reaction
Positive and Negative Syndrome Scale
prediction
protein expression
protein synthesis
psychosis
quantitative analysis
RNA isolation
schizophrenia
signal transduction
smoking
genetics
Psychotic Disorders
young adult
Adult
Female
Gene Expression
Glutamate Decarboxylase
Humans
Male
Psychotic Disorders
Young Adult
Issue Date: 2017
Publisher: Public Library of Science
Citation: Yee J.Y., Nurjono M., Teo S.R., Lee T.-S., Lee J. (2017). GAD1 gene expression in blood of patients with first-episode psychosis. PLoS ONE 12 (1) : e0170805. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0170805
Abstract: ã-Aminobutyric acid (GABA), the primary inhibitory neurotransmitter, has often been studied in relation to its role in the pathophysiology of schizophrenia. GABA is synthesized from glutamate by glutamic acid decarboxylase (GAD), derived from two genes, GAD1 and GAD2. GAD1 is expressed as both GAD67 and GAD25 mRNA transcripts with the former reported to have a lower expression level in schizophrenia compared to healthy controls and latter was reported to be predominantly expressed fetally, suggesting a role in developmental process. In this study, GAD67 and GAD25 mRNA levels were measured by quantitative PCR (qPCR) in peripheral blood of subjects with first-episode psychosis (FEP) and from healthy controls. We observed low GAD25 and GAD67 gene expression levels in human peripheral blood. There was no difference in GAD25 and GAD67 gene expression level, and GAD25/ GAD67 ratio between patients with FEP and healthy controls. PANSS negative symptoms were associated with levels of GAD25 mRNA transcripts in patients with FEP. While the current study provides information on GAD25 and GAD67 mRNA transcript levels in whole blood of FEP patients, further correlation and validation work between brain regions, cerebrospinal fluid and peripheral blood expression profiling are required to provide a better understanding of GAD25 and GAD67. © 2017 Yee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/166026
ISSN: 19326203
DOI: 10.1371/journal.pone.0170805
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0170805.pdf695.03 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

3
checked on Nov 24, 2022

WEB OF SCIENCETM
Citations

2
checked on Oct 4, 2021

Page view(s)

247
checked on Nov 24, 2022

Download(s)

2
checked on Nov 24, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.